Selexis SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence

Selexis SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Selexis SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence
Selexis SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Published Sep 27, 2016
39 pages — Published Sep 27, 2016
Price US$ 250.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Selexis SA (Selexis) is a biotechnology company that develops technologies for drug discovery, cell line development and manufacture of biopharmaceutical products. The company by utilizing its technology platform develops a pipeline of technologies such as Selexis Genetic Elements, Selexis SUREtech Vectors, Selexis SUREfection Procedures, Selexis SURE CHO-M Cell Line and Selexis SURE CHO-Mplus Libraries are among others. It offers services such as cell line development, lead identification, genome characterization, MAb humanization and licensing.

Selexis SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals & Healthcare eTrack deals database, and primary and secondary research.


Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Ta

  
Source:
Document ID
GDPH137939D
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables31
  List of Figures41
Selexis SA, Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 201642
Selexis SA, Pharmaceuticals &Healthcare Deals By Type, 2010 to YTD 201661
Selexis SA, Pharmaceuticals &Healthcare, Deals By Region, 2010 to YTD 201671
Selexis SA, Pharmaceuticals &Healthcare, Deals By Therapy Area, 2010 to YTD 201681
Selexis SA, Pharmaceuticals &Healthcare, Deals Summary, 2010 to YTD 201692
Selexis SA, Pharmaceuticals &Healthcare, Deal Details1125
  Partnerships111
    Complix Partners with Selexis111
    Faron Pharma Enters into Agreement with Selexis121
    JHL Biotech Enters Into Agreement With Selexis For Drug Development131
    Selexis Enters Into Partnership Agreement With Fusion Antibodies141
    Oncobiologics Enters into Research Agreement with Selexis151
    BIOCRATES Life Sciences Enters Into Co-Development Agreement With Selexis161
    Laureate Pharma Enters Into An Agreement With Selexis171
  Licensing Agreements181
    Pieris Pharma Enters into Licensing Agreement with Selexis181
    Turgut Ilaclari Enters into Licensing Agreement with Selexis191
    Progenics Pharma Enters into Licensing Agreement with Selexis201
    Laboratorios Liomont Enters into Licensing Agreement with Selexis211
    Opthea Enters Into Licensing Agreement With Selexis For Wet AMD Product221
    Oncobiologics Exercises Option for Licensing Agreement with Selexis for ONS-1045232
    Oncobiologics Exercises Option for Licensing Agreement with Selexis for ONS-1050252
    Oncobiologics Exercises Option for Licensing Agreement with Selexis for ONS-3010272
    Selexis Expands License Agreement With Amgen291
    Selexis Enters Into Licensing Agreement With CSL301
    Selexis Enters Into Licensing Agreement With Neogenix Oncology311
  Asset Transactions321
    Agenus Enters Acquires Rights to Cell Line Development Technology from Selexis321
    Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million331
    Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis For Up To US$4.5 Million342
Selexis SA - Key Competitors361
Key Employees371
Locations And Subsidiaries381
  Head Office381
  Other Locations &Subsidiaries381
Appendix391
  Methodology391
  About GlobalData391
  Contact Us391
  Disclaimer391

Table Of Contents

About the Author


Cite this Report

  
MLA:
GlobalData Financial Mergers and Acquisitions Intelligence. "Selexis SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile" Sep 27, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Selexis-SA-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-6956>
  
APA:
GlobalData Financial Mergers and Acquisitions Intelligence. (2016). Selexis SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sep 27, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Selexis-SA-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-6956>
  
US$ 250.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research